Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results (2024)

Article Navigation

Volume 26 Issue 10 October 2024 (In Progress)

Article Contents

  • Introduction

  • Technical approach

  • Results

  • Funding

  • Data availability

  • References

  • < Previous
  • Next >

Journal Article

,

Corentin Chaumont

Department of Cardiology, Rouen University Hospital

,

1 Rue de Germont, 76031 Rouen

,

France

UNIROUEN, INSERM U1096

,

22 Boulevard Gambetta, 76183 Rouen

,

France

Search for other works by this author on:

Oxford Academic

,

Pierre Ollitrault

Department of Cardiology, Caen University Hospital

,

Caen

,

France

Search for other works by this author on:

Oxford Academic

,

Arnaud Savoure

Department of Cardiology, Rouen University Hospital

,

1 Rue de Germont, 76031 Rouen

,

France

Search for other works by this author on:

Oxford Academic

,

Raphael Al Hamoud

Department of Cardiology, Rouen University Hospital

,

1 Rue de Germont, 76031 Rouen

,

France

Search for other works by this author on:

Oxford Academic

,

Jonaz Font

Department of Cardiology, Caen University Hospital

,

Caen

,

France

Search for other works by this author on:

Oxford Academic

,

Helene Eltchaninoff

Department of Cardiology, Rouen University Hospital

,

1 Rue de Germont, 76031 Rouen

,

France

UNIROUEN, INSERM U1096

,

22 Boulevard Gambetta, 76183 Rouen

,

France

Search for other works by this author on:

Oxford Academic

,

Paul Milliez

Department of Cardiology, Caen University Hospital

,

Caen

,

France

Search for other works by this author on:

Oxford Academic

,

Laure Champ-Rigot

Department of Cardiology, Caen University Hospital

,

Caen

,

France

Search for other works by this author on:

Oxford Academic

Frederic Anselme

Department of Cardiology, Rouen University Hospital

,

1 Rue de Germont, 76031 Rouen

,

France

UNIROUEN, INSERM U1096

,

22 Boulevard Gambetta, 76183 Rouen

,

France

Corresponding author. Tel: +33 2 32 88 81 11; fax: +33 2 32 88 81 23. E-mail address: Frederic.anselme@chu-rouen.fr

Search for other works by this author on:

Oxford Academic

Corentin Chaumont and Pierre Ollitrault contributed equally to the study.

Conflict of interest: A.S., R.A.H., J.F., H.E., and P.M.: none declared; C.C. is a consultant for and has received lecture fees from Medtronic. P.O. has received consulting fees from Biotronik, Boston Scientific, Biosense Webster, Medtronic, and Zoll. L.C.-R. has received consulting fees from Boston Scientific, Medtronic, and MicroPort CRM. F.A. a is consultant for and has received lecture fees from Boston Scientific, Medtronic, and MicroPort CRM.

Author Notes

EP Europace, Volume 26, Issue 10, October 2024, euae262, https://doi.org/10.1093/europace/euae262

Published:

22 October 2024

Article history

Received:

12 September 2024

Accepted:

01 October 2024

Corrected and typeset:

22 October 2024

Published:

22 October 2024

  • PDF
  • Split View
  • Views
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
  • Cite

    Cite

    Corentin Chaumont, Pierre Ollitrault, Arnaud Savoure, Raphael Al Hamoud, Jonaz Font, Helene Eltchaninoff, Paul Milliez, Laure Champ-Rigot, Frederic Anselme, Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results, EP Europace, Volume 26, Issue 10, October 2024, euae262, https://doi.org/10.1093/europace/euae262

    Close

Search

Close

Search

Advanced Search

Search Menu

Pulsed field ablation, Atrial flutter, Cavotricuspid isthmus, Atrial fibrillation

Introduction

The efficacy and safety of pulmonary vein isolation (PVI) using pulsed field ablation (PFA) have been largely demonstrated.1–3 During atrial fibrillation (AF) catheter ablation, additional cavotricuspid isthmus (CTI) ablation is often required.4 In patients undergoing PVI using the pentaspline PFA catheter (Boston Scientific Inc., Menlo Park, USA), it remains unclear whether CTI ablation can be achieved using the same catheter. To address this question, we prospectively included all consecutive patients undergoing combined PVI and CTI ablation with the pentaspline PFA catheter in two academic hospitals from June 2023 to March 2024. All patients provided informed consent, and the study was approved by the local institutional review board.

Technical approach

All procedures were performed under general anaesthesia with uninterrupted oral anticoagulation. Pulmonary vein isolation was performed as previously described.5 The pentaspline catheter was then positioned in the right atrium, and a quadripolar catheter was positioned in the coronary sinus (CS). Cavotricuspid isthmus ablation was performed during CS ostium pacing for patients in sinus rhythm or during typical atrial flutter confirmed by entrainment manoeuvres. Based on anatomy and operators’ preference, the pentaspline catheter was positioned on the CTI using a direct approach in deployed configuration (direct ‘flower’) or indirect approach with a lateral loop in the right atrium and a semi-deployed configuration (indirect ‘basket’) (Figure 1A).

Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results (9)

Figure 1

(A) Pentaspline PFA catheter positioning during CTI ablation. (B) Sinus rhythm restoration observed after the first PFA application. Note the widely separated (105 ms) local double potentials alongside the ablation line during proximal CS pacing (stars and lines). (C) 3D electroanatomical map of the right atrium pre- and post-CTI ablation using the pentaspline PFA catheter in indirect ‘basket’ configuration. Activation maps pre- and post-ablation (top panels). Early activation is displayed as red and late activation as purple. Note the propagation block on the CTI and the late activation on the lateral side of the ablation line during proximal CS pacing. Voltage maps pre- and post-ablation (bottom panels). Normal bipolar voltage is displayed as purple. Low voltage areas are displayed across the rest of the color scale. Note the extensive low voltage (<0.05 mV) on the CTI with normal voltage (>0.5 mV) in the lateral and septal regions of the CTI. AFl, atrial flutter; CTI, cavotricuspid isthmus; IVC, inferior vena cava; PFA, pulsed field ablation; PVI, pulmonary vein isolation; TA, tricuspid annulus.

Open in new tabDownload slide

Stable positioning at the medial CTI was validated anatomically in left anterior oblique 45° and right anterior 30° oblique views, aiming to obtain right atrial near-field electrograms and right ventricular far-field electrograms on the pentaspline catheter. A bolus of nitroglycerin (2 mg) was administered via the femoral venous sheath 1–5 min prior to the first PFA application. A minimum of four PFA applications were delivered, with at least two additional applications after achieving CTI block. The total number of applications was at the operators’ discretion. Twelve-lead ECG was monitored continuously, focusing on ST-segment changes. Complete bidirectional CTI block was defined according to the differential pacing technique previously described.6 The presence of widely spaced (>100 ms) double atrial potentials along the ablation line was also assessed.7

Results

This cohort included 32 consecutive patients (Table 1). Cavotricuspid isthmus ablation was performed with the pentaspline PFA catheter in a direct ‘flower’ configuration for 21 patients (66%) and indirect ‘basket’ configuration for 9 patients (28%). Both configurations were used in two patients (6%). Sinus rhythm restoration was observed after the first PFA application in 17/19 patients (89%) with ongoing typical atrial flutter (Figure 1B). The median number of PFA applications was 6, interquartile range (IQR) 5–8 in ‘flower’ configuration, and 6, IQR 6–10 in ‘basket’ configuration. Acute bidirectional conduction block within the CTI was obtained in all patients. Widely separated (>100 ms) local double potentials alongside the ablation line could be recorded by the pentaspline catheter in 21 patients (66%) and clearly appeared after the first PFA application in 17/21 patients. Double potentials were visualized in all the nine ‘basket-only’ configuration cases and in 12/23 cases (52%) using ‘flower’ configuration, either ‘flower-only’ or ‘flower-basket’ (P = 0.01) (Figure 1B). The mean duration from insertion of the PFA catheter into the right atrium to completion and assessment of complete CTI block was 8.2 ± 2.6 min. After 20-min waiting period, none of the patients exhibited conduction recovery across the CTI. None of the patients developed atrio-ventricular (AV) conduction disturbance, ST-segment elevation, or haemodynamic instability following the PFA applications. There were no notable clinical haemodynamic consequences after nitroglycerin injection. In the five patients who underwent 3D electroanatomical mapping pre- and post-CTI ablation for illustrative purpose, the voltage maps showed extensive low voltage and propagation block on the CTI, but with normal voltage in the lateral and septal regions of the CTI, notably at the triangle of Koch (Figure 1C). At 6-month follow-up, 30/32 patients (94%) did not experience symptom recurrence and were in sinus rhythm on 12-lead ECG. Two patients experienced left atrial arrhythmia recurrences and underwent redo procedures with 3D electroanatomical mapping, showing persistent bidirectional block along the CTI. There was no acute coronary event during the follow-up period.

Table 1

Open in new tab

Patients baseline characteristics

Baseline characteristicsAll patients (n = 32) mean ± SD, median (IQR) or n (%)
Age, years62 ± 8
Sex (male)27 (84)
AF type
 Paroxysmal13 (41)
 Persistent19 (59)
Indication for CTI ablation
 Documented typical AFl before the procedure13 (41)
 Typical AFl at the beginning of the procedure8 (25)
 Typical AFl induced during the procedure11 (34)
Hypertension17 (53)
Diabetes5 (16)
History of stroke or TIA2 (6)
Coronary artery disease (stent or CABG)3 (9)
Heart failure13 (41)
CHA2DS2-VASc2 (1–3)
Body mass index, kg/m228 ± 4
LVEF
 LVEF > 50%20 (63)
 LVEF 40–50%4 (13)
 LVEF < 40%8 (25)
Antiarrhythmic medications
 Class Ic9 (28)
 Amiodarone13 (41)
Baseline characteristicsAll patients (n = 32) mean ± SD, median (IQR) or n (%)
Age, years62 ± 8
Sex (male)27 (84)
AF type
 Paroxysmal13 (41)
 Persistent19 (59)
Indication for CTI ablation
 Documented typical AFl before the procedure13 (41)
 Typical AFl at the beginning of the procedure8 (25)
 Typical AFl induced during the procedure11 (34)
Hypertension17 (53)
Diabetes5 (16)
History of stroke or TIA2 (6)
Coronary artery disease (stent or CABG)3 (9)
Heart failure13 (41)
CHA2DS2-VASc2 (1–3)
Body mass index, kg/m228 ± 4
LVEF
 LVEF > 50%20 (63)
 LVEF 40–50%4 (13)
 LVEF < 40%8 (25)
Antiarrhythmic medications
 Class Ic9 (28)
 Amiodarone13 (41)

AF, atrial fibrillation; AFl, atrial flutter; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack.

Table 1

Open in new tab

Patients baseline characteristics

Baseline characteristicsAll patients (n = 32) mean ± SD, median (IQR) or n (%)
Age, years62 ± 8
Sex (male)27 (84)
AF type
 Paroxysmal13 (41)
 Persistent19 (59)
Indication for CTI ablation
 Documented typical AFl before the procedure13 (41)
 Typical AFl at the beginning of the procedure8 (25)
 Typical AFl induced during the procedure11 (34)
Hypertension17 (53)
Diabetes5 (16)
History of stroke or TIA2 (6)
Coronary artery disease (stent or CABG)3 (9)
Heart failure13 (41)
CHA2DS2-VASc2 (1–3)
Body mass index, kg/m228 ± 4
LVEF
 LVEF > 50%20 (63)
 LVEF 40–50%4 (13)
 LVEF < 40%8 (25)
Antiarrhythmic medications
 Class Ic9 (28)
 Amiodarone13 (41)
Baseline characteristicsAll patients (n = 32) mean ± SD, median (IQR) or n (%)
Age, years62 ± 8
Sex (male)27 (84)
AF type
 Paroxysmal13 (41)
 Persistent19 (59)
Indication for CTI ablation
 Documented typical AFl before the procedure13 (41)
 Typical AFl at the beginning of the procedure8 (25)
 Typical AFl induced during the procedure11 (34)
Hypertension17 (53)
Diabetes5 (16)
History of stroke or TIA2 (6)
Coronary artery disease (stent or CABG)3 (9)
Heart failure13 (41)
CHA2DS2-VASc2 (1–3)
Body mass index, kg/m228 ± 4
LVEF
 LVEF > 50%20 (63)
 LVEF 40–50%4 (13)
 LVEF < 40%8 (25)
Antiarrhythmic medications
 Class Ic9 (28)
 Amiodarone13 (41)

AF, atrial fibrillation; AFl, atrial flutter; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack.

This is the first real-life case series of consecutive patients undergoing CTI ablation using a pentaspline PFA catheter. This approach was successfully and safely performed in 32 cases. We observed a high acute efficacy with sinus rhythm restoration after the first PFA application in 89% of patients and persistence of a bidirectional CTI block after a 20-min waiting period in all. The direct ‘flower’ or indirect ‘basket’ approaches were similarly efficient with a median number of six applications. The safety profile also appeared satisfactory with no patients developing AV conduction disturbance or ST-segment elevation, under cover of a 2 mg bolus of nitroglycerin. The pentaspline PFA catheter has been developed to perform PVI only but CTI ablation is often required during AF ablation procedure. Using the same catheter to perform both PVI and CTI ablation could be time and cost-saving. Moreover, this could reduce the carbon footprint of the procedure.8 Some concerns have been raised about the risk of coronary spasm associated with the use of the PFA catheter in the CTI. In patients undergoing CTI ablation with a focal PFA catheter, vasospasm of the right coronary artery (RCA) was observed in four of five patients (80%) without nitroglycerin injection.9 Similar results were found with the pentaspline PFA catheter: subtotal vasospasm of the RCA was observed in all patients without nitroglycerin injection whereas only mild to moderate vasospasm occurred in 20% of patients after the administration of intracoronary or intravenous nitroglycerin.10 None of these vasospastic events resulted in ST-segment elevation or arrhythmias.9,10 Contrary to radiofrequency ablation,11,12 it appeared that PFA-induced vasospasm does not lead to any discernible degree of coronary stenosis.13 Intracoronary injection of nitroglycerin appeared unnecessary as an intravenous injection before the first PFA application seemed to be a safe approach.

The optimal number of PFA applications, especially after obtaining CTI block, remains to be determined in order to prevent late reconduction. The safety profile of CTI ablation using the pentaspline PFA catheter observed in our study also has to be further confirmed in larger cohorts.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability

The data that support the findings of this study are available on request from the corresponding author, F.A.

References

1

Turagam

MK

,

Neuzil

P

,

Schmidt

B

,

Reichlin

T

,

Neven

K

,

Metzner

A

et al.

Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry

.

Circulation

2023

;

148

:

35

46

.

2

Schmidt

B

,

Bordignon

S

,

Neven

K

,

Reichlin

T

,

Blaauw

Y

,

Hansen

J

et al.

EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry

.

Europace

2023

;

25

:

euad185

.

3

Della Rocca

DG

,

Marcon

L

,

Magnocavallo

M

,

Menè

R

,

Pannone

L

,

Mohanty

S

et al.

Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: a propensity score-matched comparison

.

Europace

2023

;

26

:

euae016

.

4

Calkins

H

,

Hindricks

G

,

Cappato

R

,

Kim

Y-H

,

Saad

EB

,

Aguinaga

L

et al.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

.

Heart Rhythm

2017

;

14

:

e275

444

.

5

Chaumont

C

,

Hayoun

C

,

Savoure

A

,

Al Hamoud

R

,

Auquier

N

,

McDonnell

E

et al.

Pentaspline pulsed field ablation catheter versus cryoballoon for atrial fibrillation ablation: results from a prospective comparative study

.

J Am Heart Assoc

2024

;

13

:

e033146

.

6

Shah

D

,

Haïssaguerre

M

,

Takahashi

A

,

Jaïs

P

,

Hocini

M

,

Clémenty

J

.

Differential pacing for distinguishing block from persistent conduction through an ablation line

.

Circulation

2000

;

102

:

1517

22

.

7

Anselme

F

,

Savouré

A

,

Cribier

A

,

Saoudi

N

.

Catheter ablation of typical atrial flutter: a randomized comparison of 2 methods for determining complete bidirectional isthmus block

.

Circulation

2001

;

103

:

1434

9

.

8

Sacher

F

,

Bacquelin

R

,

Bessiere

F

,

Ditac

G

,

Duchateau

J

,

Ait-Said

M

et al.

Position paper on sustainability in cardiac pacing and electrophysiology from the working group of cardiac pacing and electrophysiology of the French Society of Cardiology

.

Arch Cardiovasc Dis

2024

;

117

:

224

31

.

9

Malyshev

Y

,

Neuzil

P

,

Petru

J

,

Funasako

M

,

Hala

P

,

Kopriva

K

et al.

Nitroglycerin to ameliorate coronary artery spasm during focal pulsed-field ablation for atrial fibrillation

.

JACC Clin Electrophysiol

2024

;

10

:

885

96

.

10

Reddy

VY

,

Petru

J

,

Funasako

M

,

Kopriva

K

,

Hala

P

,

Chovanec

M

et al.

Coronary arterial spasm during pulsed field ablation to treat atrial fibrillation

.

Circulation

2022

;

146

:

1808

19

.

11

Ouali

S

,

Anselme

F

,

Savouré

A

,

Cribier

A

.

Acute coronary occlusion during radiofrequency catheter ablation of typical atrial flutter

.

J Cardiovasc Electrophysiol

2002

;

13

:

1047

9

.

12

Bussmann

BM

,

De Maria

GL

,

Kotronias

RA

,

Rajappan

K

,

Green

PG

,

Pedersen

M

.

Acute right coronary artery occlusion following cavotricuspid isthmus ablation

.

JACC Cardiovasc Interv

2024

;

17

:

97

8

.

13

Malyshev

Y

,

Neuzil

P

,

Petru

J

,

Funasako

M

,

Hala

P

,

Kopriva

K

et al.

Does acute coronary spasm from pulsed field ablation translate into chronic coronary arterial lesions?

JACC Clin Electrophysiol

2024

;

10

:

970

2

.

Author notes

Corentin Chaumont and Pierre Ollitrault contributed equally to the study.

Conflict of interest: A.S., R.A.H., J.F., H.E., and P.M.: none declared; C.C. is a consultant for and has received lecture fees from Medtronic. P.O. has received consulting fees from Biotronik, Boston Scientific, Biosense Webster, Medtronic, and Zoll. L.C.-R. has received consulting fees from Boston Scientific, Medtronic, and MicroPort CRM. F.A. a is consultant for and has received lecture fees from Boston Scientific, Medtronic, and MicroPort CRM.

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Issue Section:

Research letter

Download all slides

Advertisement intended for healthcare professionals

Citations

Views

194

Altmetric

More metrics information

Metrics

Total Views 194

144 Pageviews

50 PDF Downloads

Since 10/1/2024

Month: Total Views:
October 2024 194

Citations

Powered by Dimensions

Altmetrics

×

Email alerts

Article activity alert

Advance article alerts

New issue alert

In progress issue alert

Receive exclusive offers and updates from Oxford Academic

Citing articles via

Google Scholar

  • Latest

  • Most Read

  • Most Cited

What the Blood Knows: Predicting Atrial Fibrillation Risk in Hypertrophic Cardiomyopathy Patients
Prediction of New-onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Plasma Proteomics Profiling
Comparative Effects of Different Power Settings for Achieving Transmural Isolation of the Left Atrial Posterior Wall with Radiofrequency Energy
Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results
Are Drivers Recurring or Ephemeral? Observations from Serial Mapping of Persistent Atrial Fibrillation

More from Oxford Academic

Cardiovascular Medicine

Clinical Medicine

Medicine and Health

Books

Journals

Advertisement intended for healthcare professionals

Cavotricuspid isthmus ablation using a pentaspline pulsed field ablation catheter: feasibility and acute results (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Foster Heidenreich CPA

Last Updated:

Views: 6374

Rating: 4.6 / 5 (76 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Foster Heidenreich CPA

Birthday: 1995-01-14

Address: 55021 Usha Garden, North Larisa, DE 19209

Phone: +6812240846623

Job: Corporate Healthcare Strategist

Hobby: Singing, Listening to music, Rafting, LARPing, Gardening, Quilting, Rappelling

Introduction: My name is Foster Heidenreich CPA, I am a delightful, quaint, glorious, quaint, faithful, enchanting, fine person who loves writing and wants to share my knowledge and understanding with you.